

# AtheroSclerotic CardioVascular Disease


## Prevention








## Hypertension in the U.S.





• JAMA November 6, 2018


## Hypertension in Iran





• BMC Cardiovasc Disord 2010; 10: 61

# A 10 mm Hg reduction in systolic blood pressure can significantly reduce risk of several conditions:





### Hypertension and total cardiovascular risk assessment

Hypertension rarely occurs in isolation, and often clusters with other cardiovascular risk factors such as dyslipidemia and glucose intolerance.

This metabolic risk factor clustering has a multiplicative effect on cardiovascular risk Quantification of total cardiovascular risk is an important part of the risk stratification process for patients with hypertension.

## **Diagnosis of high blood pressure**




## Identification of a number of specific BP patterns

- Combined use of office and out-of-office blood pressure measurements allows identification of a number of specific BP patterns, characterized by discrepant levels of office and out-of-office BP.
- Evidence has been provided in this regard showing that both WCH and MH in untreated individuals and WCUH and MUCH in treated patients are associated to an increased risk of major cardiovascular outcomes and hypertension related hospitalization.



## **Identification of a number of specific BP patterns**





International Journal of Cardiology 331 (2021) 262–269


## Hypertension Diagnosis



- The measurement of BP in the office or clinic is most commonly the basis for hypertension diagnosis and follow-up.
- Whenever possible, the diagnosis should not be made on a single office visit. Usually 2–3 office visits at 1–4-week intervals are required. The diagnosis might be made on a single visit, if BP is ≥180/110 mmHg and there is evidence of CVD.
- If possible and available, the diagnosis of hypertension should be confirmed by **out-of-office** BP measurement.



## **Blood Pressure Measurement**





## Blood Pressure Measurement Plan

Office	e Blood Pressure Levels (mr	m Hg)
<130/85	130-159/8599	>160/100
Remeasure within 3 years (1 year in those with other risk factors)	If possible confirm with out-of-office blood pressure measurement (high possibility of white coat or masked hypertension). Alternatively confirm with repeated office visits.	Confirm within a few days or weeks



## Diagnostic/ Clinical Tests





#### **1. Blood pressure:**

- New onset hypertension
- duration
- previous BP levels
- current and previous antihypertensive medication
- other medications
- history of intolerance of antihypertensive medications
- adherence to antihypertensive treatment
- previous hypertension with oral contraceptives or pregnancy



#### Medical History (ESSENTIAL)

#### 2. Risk factors / Assessment of overall CV risk:

- Personal history of CVD
  - MI

**Diagnostic**/

**Clinical Tests** 

- HF
- Stroke
- TIA
- DM
- Dyslipidemia
- CKD

- Lifestyle habits
  - smoking status
  - Diet
  - alcohol intake
  - physical activity
  - psychosocial aspects
  - history of depression

- Family history of
  - Hypertension
  - premature CVD
  - (familial) hypercholesterolemia
  - diabetes.



## Diagnostic / Clinical Tests

**Medical History** 

#### ESSENTIAL

# 3. Symptoms/signs of hypertension/coexistent illnesses:

- Chest pain
- shortness of breath
- Palpitations
- Claudication
- peripheral edema
- Headaches
- blurred vision
- Nocturia
- Hematuria
- dizziness



Medical History (ESSENTIAL)

# 4. Symptoms suggestive of secondary hypertension:

- Muscle weakness/tetany
- Cramps
- arrhythmias (hypokalemia/primary aldosteronism)
- flash pulmonary edema (renal artery stenosis)
- Sweating
- palpitations
- frequent headaches (pheochromocytoma)
- snoring,
- daytime sleepiness (obstructive sleep apnea)
- symptoms suggestive of thyroid disease



## Diagnostic / Clinical Tests

### **Physical Examination**

#### 1. Circulation and heart:

- Pulse rate/rhythm/character
- jugular venous pulse/pressure
- apex beat

**Diagnostic**/

**Clinical Tests** 

- extra heart sounds
- basal crackles, peripheral edema
- bruits (carotid, abdominal, femoral)
- radio-femoral delay

#### 2. Other organs/systems:

ESSENTIAL

- Enlarged kidneys
- neck circumference >40 cm (obstructive sleep apnea)
- enlarged thyroid
- BMI / waist circumference
- fatty deposits and colored striae (Cushing disease/syndrome).



Diagnostic/ Clinical Tests

### Laboratory Investigations and ECG (ESSENTIAL

#### • Blood tests:

• Sodium, potassium, serum creatinine and eGFR. If available, lipid profile and fasting glucose.

#### • Urine test:

- Dipstick urine test.
- 12-lead ECG:
  - Detection of AF, LVH, ischemic heart disease.



- 50% < hypertensive patients have additional CV risk factors.</li>
  - The most common additional risk factors are:





## Cardiovascular Risk Factors

## **Treatment of Hypertension**



## **Classification of office BP and definitions of hypertension grade**

Category	Systolic (mmHg)		Diastolic (mmHg)
Optimal	<120	and	<80
Normal	120–129	and/or	80-84
High normal	130–1 <mark>3</mark> 9	and/or	85-89
Grade 1 hypertension	140–159	and/or	90-99
Grade 2 hypertension	160–179	and/or	100-109
Grade 3 hypertension	≥180	and/or	≥110
Isolated systolic hypertension <sup>b</sup>	≥140	and	<90



• European Heart Journal (2018) 39, 3021–3104

## **10 Year CV risk Categories**

Very high risk	People with any of the following:						
	Documented CVD, either clinical or unequivocal on imaging.						
	<ul> <li>Clinical CVD includes acute myocardial infarction, acute coronary syndrome, coronary or other arterial revascula- rization, stroke, TIA, aortic aneurysm, and PAD</li> </ul>						
	• Unequivocal documented CVD on imaging includes significant plaque (i.e. ≥50% stenosis) on angiography or ultrasound; it does not include increase in carotid intima-media thickness						
	<ul> <li>Diabetes mellitus with target organ damage, e.g. proteinuria or a with a major risk factor such as grade 3 hypertension or hypercholesterolaemia</li> </ul>						
	• Severe CKD (eGFR <30 mL/min/1.73 m <sup>2</sup> )						
	<ul> <li>A calculated 10 year SCORE of ≥10%</li> </ul>						
High risk	People with any of the following:						
	<ul> <li>Marked elevation of a single risk factor, particularly cholesterol &gt;8 mmol/L (&gt;310 mg/dL), e.g. familial hyper- cholesterolaemia or grade 3 hypertension (BP ≥180/110 mmHg)</li> </ul>						
	• Most other people with diabetes mellitus (except some young people with type 1 diabetes mellitus and with- out major risk factors, who may be at moderate-risk)						
	Hypertensive LVH						
	Moderate CKD eGFR 30-59 mL/min/1.73 m <sup>2</sup> )						
	A calculated 10 year SCORE of 5-10%						



### **10 Year CV risk Categories**

Moderate risk	<ul> <li>People with:</li> <li>A calculated 10 year SCORE of ≥1 to &lt;5%</li> <li>Grade 2 hypertension</li> <li>Many middle-aged people belong to this category</li> </ul>
Low risk	<ul> <li>People with:</li> <li>A calculated 10 year SCORE of &lt;1%</li> </ul>




• European Heart Journal (2018) 39, 3021–3104

Unsertension			BP (mmHg) grading							
disease	Other risk factors, HMOD, or disease	High normal SBP 130-139 DBP 85-89	Grade 1 SBP 140-159 DBP 90-99	Grade 2 SBP 160-179 DBP 100-109	Grade 3 SBP ≥180 or DBP ≥110					
	No other risk factors	Low risk	Low risk	Moderate risk	High risk					
Stage 1 (uncomplicated) 1 or 2 risk factors ≥3 risk factors	Low risk	Moderate risk	Moderate to high risk	High risk						
	≥3 risk factors	Low to Moderate risk	Moderate to high risk	High Risk	High risk					
Stage 2 (asymptomatic disease)	HMOD, CKD grade 3, or diabetes mellitus without organ damage	Moderate to high risk	High risk	High risk	High to very high risk					
Stage 3 (established disease)	Established CVD, CKD grade ≥4, or diabetes mellitus with organ damage	Very high risk	Very high risk	Very high risk	Very high risk					



## When to initiate antihypertensive treatment?





Baseline SBP, mm Hg	No. of Events/ Participants/Trials	RR (95% CI)	Favors Treatment	Favors Control	Heterogeneity 1 <sup>2</sup> Value, %
All-cause mortality		- montain an ann an Ann	0.00244.000.0000		44 - 1646-1868-1868-1868-1868-1868-1868-1868-
<140	4897/68816/16	0.98 (0.90-1.06)	4		11.6
140-159	2731/41049/15	0.87 (0.75-1.00)	$\diamond$		43.2
≥160	4361/79900/18	0.93 (0.87-1.00)	\$		17.0
SBP interaction, P=.18					
Cardiovascular mortality					
<140	2633/66480/12	1.03 (0.87-1.20)	<		43.4
140-159	1465/42587/15	0.86 (0.65-1.14)	$\bigcirc$	<b>*</b>	57.9
≥160	2290/78789/17	0.85 (0.77-0.95)	$\diamond$		18.0
SBP interaction, P=.02					
Major cardiovascular events					
<140	7354/67928/13	0.97 (0.90-1.04)	•		30.6
140-159	3951/43489/16	0.88 (0.80-0.96)	\$		31.0
≥160	4627/77733/16	0.78 (0.70-0.87)	♦		53.8
SBP interaction, P=.004					

- Primary preventive BP lowering is associated with reduced risk for death and CVD if baseline SBP is 140 mm Hg or higher.
- At lower BP levels, treatment is not associated with any benefit in primary prevention but might offer additional protection *in patients with CHD*.



• JAMA Intern Med. 2018;178(1):28-36.

4 8	1.20 (0.51-2.78)		
	0.40 (0.20-0.81)	0.006	
4	1.25 (0.82-1.92)		
4	1.00 (0.60-1.84)	0.089	
1	-		
1	0.82 (0.38-1.81)	2	
3	1.27 (0.88-1.81)	200 B (B B) (C B)	
8	0.65 (0.52-0.80)	<0.001	
5	1.02 (0.73-1.39)	100.000.00	
6	0.91 (0.66-1.29)	0.32	
3	1.23 (0.74-2.06)		
6	0.66 (0.40-1.09)	0.001	· · · · ·
10	1.18 (0.88-1.60)		
6	0.77 (0.54-1.13)	0.016	
		0.000	
		0.2	0.5 1.0 2.0 5.0
	3 8 5 6 3 6 10 6	5         1.02 (0.73-1.39)           6         0.91 (0.66-1.29)           3         1.23 (0.74-2.06)           6         0.66 (0.40-1.09)	5       1.02 (0.73-1.39)       0.32         6       0.91 (0.66-1.29)       0.32         3       1.23 (0.74-2.06)       0.001         6       0.66 (0.40-1.09)       0.001


Individuals with very high cardiovascular risk due to symptomatic cardiovascular disease should consider BP-lowering treatment even when their BP is in the high-normal range.



• J Hypertens 2017;35:2150–2160.

### Initiation of treatment In Patients with Grade 2 or 3 HTN

Prompt initiation of BP-lowering drug treatment is recommended in patients with grade 2 or 3 HTN **at any level of CV risk**, simultaneous with the initiation of lifestyle changes.



Active better Control better



• European Heart Journal (2018) 39, 3021–3104 , Journal of Hypertension (2014) 32:2285–2295

## **Office BP treatment targets in hypertensive patients**

Age group		Office SBP treatment target ranges (mmHg)						
	Hypertension	+ Diabetes	+ CKD	+ CAD	+ Stroke <sup>a</sup> /TIA			
18-65 years	Target to 130 or lower if tolerated Not <120	Target to 130 or lower if tolerated Not <120	Target to <140 to 130 if tolerated	Target to 130 or lower if tolerated Not <120	Target to 130 or lower if tolerated Not <120	70–79		
65 - 79 years <sup>b</sup>	Target to 130-139	Target to 130-139	Target to 130-139 if tolerated	Target to 130-139 if tolerated	Target to 130-139 if tolerated	70–79		
≥80 years <sup>b</sup>	Target to 130-139	Target to 130-139	Target to 130-139 if tolerated	Target to 130-139 if tolerated	Target to 130-139 if tolerated	70-79		
Office DBP treatment target range (mmHg)	7079	70–79	70–79	70–79	70–79			



• European Heart Journal (2018) 39, 3021–3104

	Studies	Intervention		tervention Control		RR (95% CI) per 10 mm Hg reduction in systolic blood pressure		
		Events	Participants	Events	Participants			
Major cardiovascular	events							0.22
<130	4	542	4547	530	3881		0.63 (0.50-0.80)	
130-139	17	5375	47103	5856	47167	+	0-87 (0-82-0-92)	
140-149	7	4365	33333	4694	33062	The second secon	0.79 (0.72-0.87)	
150-159	13	1289	21290	1257	20088		0-80 (0-71-0-91)	
≥160	14	1638	31045	1731	24060		0.74 (0.69-0.79)	
Total						•	0-80 (0-77-0-83)	
Coronary heart diseas	se .							0.93
<130	5	489	6071	620	5395		0-55 (0-42-0-72)	
130-139	18	2258	47608	2461	47670		0-88 (0-80-0-96)	
140-149	8	1225	34834	1307	34581	-#	0.80 (0.69-0.94)	
150-159	12	409	20386	442	19788		0.84 (0.68-1-05)	
≥160	13	481	28086	471	21113		0-82 (0-73-0-92)	
Total						•	0-83 (0-78-0-88)	
Stroke								0.38
<130	3	48	3669	47	2984		0.65 (0.27-1.57)	
130-139	18	1191	47608	1403	47670		0.73 (0.62-0.85)	
140-149	7	2130	34166	2381	34347		0-78 (0-70-0-87)	
150-159	11	538	19636	702	19026		0.65 (0.54-0.78)	
≥160	15	728	31603	845	24613		0.70 (0.64-0.78)	
					0-33 RR per	0-50 1 10 mm Hg reduction in systoli		

Favours intervention

Favours control

Cardio Thrombosis

• Lancet 2016; 387: 957–67

Studies	Intervention

Control

#### RR (95% CI) per 10 mm Hg pund reduction in systolic blood pressure

		Events	Participants	Events	Participants					
Heart failure										0.27
<130	3	137	3669	138	2984				0.83 (0.41-1.70)	
130-139	15	1493	44 0 29	1778	44104		-98-		0.75 (0.66-0.85)	
140-149	6	1121	32665	1207	32828				0.83 (0.70-1.00)	
150-159	7	304	8507	271	7945			_	0.96 (0.71-1.30)	
≥160	12	229	26541	366	19579		-		0.61 (0.54-0.70)	
Total							•		0.72 (0.67-0.78)	
Renal failure										0.52
130-139	5	320	14661	317	14711		-+		1-02 (0-82-1-26)	
140-149	2	76	10945	60	11045				→ 3·23 (0·73-14·30)	
150-159	4	464	7278	428	6755			8	0.90 (0.76-1-05)	
≥160	5	30	7004	29	6532				0.94 (0.56-1.56)	
Total							-		0-95 (0-84-1-07)	
All-cause mortality										0.79
<130	7	320	7733	410	7059		_		0.53 (0.37-0.76)	
130-139	18	3596	47608	3782	47670		-		0.89 (0.82-0.98)	
140-149	7	3338	34166	3318	34347		- 100		0.99 (0.89-1-09)	
150-159	12	1127	20705	1197	19511		-10-		0.78 (0.69-0.90)	
≥160	13	1394	28086	1291	21113				0.86 (0.80-0.92)	
Total							٠		0-87 (0-84-0-91)	
					0-3	3 0-50	1	2		
							g reduction	in systolic bloo	d pressure	
						avours interv	tine			
					- F	avours interv	vention	Favours contr	01	




# Treatment of hypertension

- Lifestyle changes
- Pharmacological therapy



• European Heart Journal (2018) 39, 3021–3104

## **Lifestyle Modification**





## **Ideal Characteristics of Drug Treatment**

1	Treatments should be evidence-based in relation to morbidity/mortality prevention.
2	Use a once-daily regimen which provides 24-hour blood pressure control.
3	Treatment should be affordable and/or cost-effective relative to other agents.
4	Treatments should be well-tolerated.
5	Evidence of benefits of use of the medication in populations to which it is to be applied.



## **Oral Antihypertensive Drugs**

#### Primary agents


	Class	Drug	Daily Freq.
1	Thiazide or Thiazide-type diuretics	Chlorthalidone	1
		Hydrochlorothiazide	1
		Indapamide	1
2	ACE inhibitors	Benazepril	1 or 2
		Captopril	2 or 3
		Enalapril	1 or 2
3	ARBs	Losartan	1 or 2
		Telmisartan	1
		Valsartan	1
4	CCB dihydropyridines	Amlodipine	1
		Nifedipine LA	1
	CCB nondihydropyridines	Diltiazem SR	2
		Verapamil SR	1 or 2

#### Secondary agents

Class	Drug	Daily Freq.
Diuretics— loop	Furosemide	2
Diuretics	Amiloride	1 or 2
potassium sparing	Triamterene	1 or 2
Aldosterone antagonists	Spironolactone	1
	Atenolol	
	Bisoprolol	1
Poto blockors	Metoprolol tartrate	2
Beta blockers	Nebivolol	1
	Propranolol IR	2
	Carvedilol	2
Alpha-1 blockers	Terazosin	1 or 2
Control alpha1 aganist	Clonidine oral	2
Central alpha1 agonist	Methyldopa	2
Direct vasodilators	Hydralazine	2 or 3

• Hypertension. 2018;71:e13-e115.

## Core drug treatment strategy for uncomplicated HTN





## The drug treatment algorithm for HTN

- 1. The initiation of treatment in most patients with an SPC comprising two drugs, to improve the speed, efficiency, and predictability of BP control.
- 2. A beta-blocker in combination with a diuretic or any drug from the other major classes is an alternative when there is a specific indication for a beta-blocker, e.g. angina, post-myocardial infarction, heart failure, or heart rate control.
- 3. Use monotherapy for:
  - a) low-risk patients with stage 1 hypertension
  - b) very high-risk patients with high-normal BP
  - c) frail older patients



• European Heart Journal (2018) 39, 3021–3104

## **Combination Therapy**

Patients initiated with combination:

- Required less titration steps
- Reached the goal of BP in a shorter period of time
- Achieve higher BP control rates and greater reductions in both systolic and diastolic BP from baseline



### **Adherence to Antihypertensive Treatment**

- Nonadherence to antihypertensive treatment affects 10%–80% of hypertensive patients and is one of the key drivers of suboptimal BP control.
- Evaluate adherence to antihypertensive treatment as appropriate at each visit and prior to escalation of antihypertensive treatment



## **Adherence to Antihypertensive Treatment**

Consider the following strategies to improve medication adherence:

- 1. reducing polypharmacy use of **single pill combinations**
- 2. **once-daily dosing** over multiple times per day dosing
- 3. linking adherence behavior with daily habits
- 4. providing adherence feedback to patients
- 5. home BP monitoring
- 6. reminder packaging of medications
- 7. empowerment-based counseling for self-management
- 8. electronic adherence aids such as mobile phones or short messages services
- 9. multidisciplinary healthcare team approach to improve monitoring for adherence



## **Treatment strategies in people with diabetes**

Recommendations	Class	Level
<ul> <li>In people with diabetes receiving BP-lowering drugs it is recommended:</li> <li>To target SBP to 130 mmHg and <ul> <li>&lt;130mmHg if tolerated, but not</li> <li>&lt;120 mmHg.</li> </ul> </li> <li>In older people (aged &gt;_65 years aged), to target to an SBP range of 130–139 mmHg.</li> <li>To target the DBP to &lt;80 mmHg, but not &lt;70 mmHg.</li> </ul>		A
It is recommended to initiate treatment with a combination of a RAS blocker with a CCB or thiazide/thiazide-like diuretic.		А
Simultaneous administration of two RAS blockers, e.g. an ACE inhibitor and ARB, is not indicated.		А



## **Treatment strategies in people with CKD**

Recommendations	Class	Level
In patients with diabetic or non-diabetic CKD: • It is recommended to lower SBP to a range of 130–139 mmHg.		А
<ul> <li>Individualized treatment should be considered according to its tolerability and impact on renal function and electrolytes.</li> </ul>	lla	С
RAS blockers are more effective at reducing albuminuria than other antihypertensive agents, and are recommended as part of the treatment strategy in hypertensive patients in the presence of microalbuminuria or proteinuria.		A
A combination of a RAS blocker with a CCB or a diuretic is recommended as initial therapy.	I	А



• European Heart Journal (2018) 39, 3021–3104

## Treatment strategies in secondary stroke prevention

Recommendations	Class	Level
In all hypertensive patients with ischemic stroke or TIA, an SBP target range of 120–130 mmHg should be considered.		В
The recommended antihypertensive drug treatment strategy for stroke prevention is a RAS blocker plus a CCB or a thiazide-like diuretic.	I	А



• European Heart Journal (2018) 39, 3021–3104

## Diuretics

Consider ACEIs or ARBs + Thiazide-**like** diuretic in:


- Post-stroke
- Very elderly
- Incipient HF
- CCB intolerance



## Choice of diuretic therapy

#### Hypertension in the Very Elderly Trial (HYVET)

E Heart Failure



Antihypertensive treatment with indapamide ER, with or without perindopril, in persons 80 years of age or older is beneficial.



## **Blood Pressure Goals**



**BP** Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions

Clinical Condition(s)	BP Threshold, mm Hg	BP Goal, mm Hg
General		
Clinical CVD or 10-year ASCVD risk ≥10%	≥130/80	<130/80
No clinical CVD and 10-year ASCVD risk <10%	≥140/90	<130/80
Older persons (≥65 years of age; noninstitutionalized, ambulatory, community-living adults)	≥130 (SBP)	<130 (SBP)
Specific comorbidities		
Diabetes mellitus	≥130/80	<130/80
Chronic kidney disease	≥130/80	<130/80
Chronic kidney disease after renal transplantation	≥130/80	<130/80
Heart failure	≥130/80	<130/80
Stable ischemic heart disease	≥130/80	<130/80
Secondary stroke prevention	≥140/90	<130/80
Secondary stroke prevention (lacunar)	≥130/80	<130/80
Peripheral arterial disease	≥130/80	<130/80

Cardio Thrombosis

# Why is Single Pill Combination recommended for initial therapy?





- Most patients with hypertension require multiple agents for control of their blood pressure.
- Many patients started on a single agent will subsequently require ≥2 drugs from different pharmacological classes to reach their BP goals.
- Patients with higher blood pressures are at greater risk and more rapid titration of antihypertensive medications began to be recommended in patients with BP >20/10 mm Hg above their target.
- Initial combination therapy leads to reduced hypertension-related cardiovascular complications more effectively than monotherapy.
- Fixed-dose combinations simplify therapeutic regimen.
- Use of combination therapy may also improve adherence.



Hypertension. 2018;71:e13–e115 American Journal of Hypertension 31(3) March 2018/International Journal of Cardiology 331 (2021) 262–269




Combination therapy is the suggested way to increase treatment efficacy while combined agents also may minimize the adverse effects of each individual agent.

- Thiazide diuretics may stimulate the RAAS. By adding an ACEI or ARB to the thiazide, an additive BP-lowering effect may be obtained.
- Studies show treatment with amlodipine/valsartan 5/160 mg induced significantly less peripheral **edema** than amlodipine 10 mg for similar BP reduction.



### Factors affecting adherence to antihypertensive treatment







#### **Consequences of Suboptimal Adherence to Antihypertensive Medications**

- 1. Uncontrolled hypertension
- 2. Progression to hypertensive crisis
- 3. Vascular stiffness
- 4. Left ventricular hypertrophy
- 5. Microalbuminuria
- 6. Myocardial infarction
- 7. Stroke
- 8. Chronic heart failure
- 9. Chronic kidney and end-stage renal disease
- 10.Cognitive dysfunction, dementia
- 11.Excess emergency department and hospital admissions
- 12.Reduced quality of life
- 13. Impaired work productivity, disability
- 14. Increased healthcare costs
- 15.Death

## Advantages of Combination Drug Therapy: Adherence Improvement

Therapeutic non-adherence is a major contributor to poor control of hypertension and a key barrier to reducing CVD deaths.

Up to 25% of patients do not fill their initial prescription for antihypertensive therapy.

During the first year of treatment, the average patient has possession of antihypertensive medications only 50% of the time, and only 1 in 5 patients has sufficiently high adherence to achieve the benefits observed in clinical trials.


Taking medications several times throughout the day requires greater attention to scheduling, as well as additional issues such as transportation or storage, which can be challenging for some patients.

Simplifying medication regimens, either by less frequent dosing or use of combination drug therapy, improves adherence.



Hypertension. 2018;71:e13-e115

#### **Combination Therapy** More Adherence, More BP Goal Achievements






#### **Antihypertensive Medication Adherence Strategies**

COR	LOE	Recommendations for Antihypertensive Medication Adherence Strategies
I	B-R	In adults with hypertension, dosing of antihypertensive medication <b>once daily</b> rather than multiple times daily is beneficial to improve adherence.
lla	<b>B-NR</b> Use of <b>combination pills</b> rather than free individual components can be useful to improve adherence to antihypertensive therapy.	








Cardio Thrombosi








- From a guidelines perspective, SPCs as first line should now be viewed as having been met a reasonable minimum standard, i.e., demonstration of both reduction in BP and reduction in CV risk.
- With the appreciation of the *greater effectiveness*, *lesser rates of adverse effects*, *greater adherence*, *improved BP control rates*, and *lower risks of hypertension-related cardiovascular complications*, initial SPCs is an established if not preferred form of therapy in hypertension.



## Which combination for which patient?



## Management of Hypertension in Patients With SIHD








#### **Management of Hypertension in Patients With Heart Failure**

COR	LOE	Recommendations for Treatment of Hypertension in Patients With HF
III: No Benefit	B-R	<b>Nondihydropyridine CCBs</b> are not recommended in the treatment of hypertension in adults with HF <i>r</i> EF.

I	C-EO	In adults with HF <i>p</i> EF who present with symptoms of volume overload, diuretics should be prescribed to control hypertension.
I	C-LD	Adults with HF <i>p</i> EF and persistent hypertension after management of volume overload should be prescribed ACEI or ARBs and beta blockers titrated to attain SBP of less than 130 mm Hg.



#### Management of Hypertension in Patients With CKD







COR	LOE	Recommendations for Treatment of Hypertension in Patients With DM
I	A <sup>SR</sup>	In adults with DM and hypertension, all first-line classes of antihypertensive agents (i.e., diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective.
llb	B-NR	In adults with DM and hypertension, ACE inhibitors or ARBs may be considered in the presence of albuminuria.





#### Management of Hypertension for Secondary Stroke Prevention

COR	LOE	Recommendations for Treatment of Hypertension for Secondary Stroke Prevention
		Secondary Scioke Prevention
Ι	Α	For adults who experience a stroke or TIA, treatment with a <b>thiazide diuretic</b> , <b>ACE inhibitor</b> , or <b>ARB</b> , or combination treatment consisting of a thiazide diuretic plus ACE inhibitor, is useful.





#### **Management of Hypertension in Patients With Atrial Fibrillation**

COR	LOE	Recommendation for Treatment of Hypertension in Patients With AF
lla	B-R	Treatment of hypertension with an <b>ARB</b> can be useful for prevention of recurrence of AF.



Preventive Cardiology



Persistence and adherence to antihypertensive drugs in newly treated hypertensive patients according to initial prescription

Su-Min Jeong<sup>1,2</sup>, Shinhye Kim<sup>3,4</sup>, Dong Wook Shin<sup>5,6</sup>, Kyungdo Han<sup>7</sup>, Sang Hyun Park<sup>7</sup>, Sang Hyuk Kim<sup>8</sup>, Yul-Hee Kim<sup>9</sup> and Yong-Chol Kwon<sup>9</sup> European Journal of Preventive Cardiology 0(00) 1–4 © The European Society of Cardiology 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/2047487319900326 journals.sagepub.com/home/cpr

**SAGE** 



Study design




Explain **persistence** and **adherence** according to initial antihypertensive prescription



**SPC vs Free combination** 

#### **Persistence Rate**






## **ARB/CCB** Combination



## **CCB/ARB**(Amlodipine/Valsartan)



Amiodipine / Valsartar


## **ARB/Diuretic Combination**



#### Val-DICTATE Trial

#### ✓ Multicenter

#### ✓ Randomized




4 weeks

#### The primary end point:

% patients achieving clinic BP<140/90mmHg



#### **Val-DICTATE Trial**




ARB/Diuretic combination more effective in lowering BP & achieving BP goals than increasing the dose of the diuretic



## **ARB/CCB/Diuretic Combination**











✓ Randomized, double-blind, patients with Stage 2 hypertension





#### EXALT ABPM sub study



\*P: 0.05 by ANOVA with baseline ABP and treatment regimen as explanatory variables.


Initiating therapy of ARB/CCB with a diuretic is more effective than a maximal dose of an ARB with a diuretic



IR-1021-VLZ-6069-SP Vasc Health Risk Manag. 2011; 7: 701–708.

### **Time of Administration**






6.3-year follow up



#### The Hygia Chronotherapy Trial



BP-lowering medications at bedtime results in improved ABP control and markedly diminished occurrence of major CVD events



IR-1021-VLZ-6069-SP Eur Heart J. 2019;ehz754.

## Take home messages

Initiation of treatment with combination therapy is recommended by recent guidelines:

- ✓ More efficacy, less titration steps
- ✓ Reducing polypharmacy use of single pill combinations
- ✓ Once-daily dosing over multiple times per day dosing
- ✓ Increasing patient adherence



